SEC Company Response from Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Mar 31, 2017

Altimmune, Inc. (ALT) (CIK 0001326190)
Date: March 31, 2017 · CIK: 0001326190 · Accession: 0001144204-17-018098

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-215891

Date

March 31, 2017

Author

Philip MacNeill

Form

CORRESP

Company

Altimmune, Inc. (ALT) (CIK 0001326190)

Letter

RE: PharmAthene, Inc.

March 31, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Registration Statement on Form S-4

Filed February 3, 2017

File No. 333-215891

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, PharmAthene, Inc. (the “Registrant”) hereby requests that the effectiveness of the above-captioned Registration Statement (the “Registration Statement”) be accelerated so that it will become effective as of 5:00 p.m. ET on March 31, 2017, or as soon thereafter as practicable.

Please call Jeffrey A. Baumel of Dentons US LLP at (973) 912-7189 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
PHARMATHENE, INC.

Show Raw Text

CORRESP
1
filename1.htm

March 31, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

 RE: PharmAthene, Inc.

Registration Statement on Form S-4

Filed February 3, 2017

File No. 333-215891

Ladies and Gentlemen:

Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, PharmAthene, Inc. (the “Registrant”)
hereby requests that the effectiveness of the above-captioned Registration Statement (the “Registration Statement”)
be accelerated so that it will become effective as of 5:00 p.m. ET on March 31, 2017, or as soon thereafter as practicable.

Please call Jeffrey A. Baumel of Dentons
US LLP at (973) 912-7189 to confirm the effectiveness of the Registration Statement or with any questions.

    Very truly yours,

    PHARMATHENE, INC.

    /s/ Philip MacNeill

    Philip MacNeill

    Vice President, Chief Financial Officer,

Treasurer and Secretary

SecProbe.io